Cover Image
市場調查報告書

B細胞慢性淋巴細胞白血病:開發平台分析

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253678
出版日期 內容資訊 英文 147 Pages
訂單完成後即時交付
價格
Back to Top
B細胞慢性淋巴細胞白血病:開發平台分析 B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 147 Pages
簡介

B細胞慢性淋巴性白血病是最常見的白血病,會影響B細胞株的淋巴球。雖然致病因素尚不明,但一般認為是由於抑制血液細胞增殖的基因有1∼2個部位受損所造成。此外,家族病史也是提升發病風險的要素。由於惡化速度遲緩,許多人未能發現病徵,而是藉由定期血液檢查才發現。治療藥有錠劑型及點滴等。

本報告提供全球各國的B細胞慢性淋巴性白血病(B-CLL)治療法的開發中產品開發情形相關分析,提供開發中產品的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 調查範圍

B細胞慢性淋巴細胞白血病概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • AB Science SA
  • Amgen Inc.
  • Celgene Corporation
  • Dynavax Technologies Corporation
  • Eisai
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd.
  • iDD biotech SAS
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Molecular Templates Inc.
  • Noxxon Pharma AG
  • 小野藥品工業
  • Regeneron Pharmaceuticals, Inc.
  • TheraMAB LLC
  • Unum Therapeutics, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 202-b
  • AB-8779
  • alemtuzumab biosimilar
  • AMG-319
  • ATTCK-20
  • Cellular Immunotherapy for Hematological Malignancies
  • Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies
  • Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies
  • Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies
  • Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia
  • Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia
  • Cellular Immunotherapy to Target CD19 for B-Cell Malignancies
  • Cellular Immunotherapy to Target CD19 for Cancer
  • Cellular Immunotherapy to Target CD19 for Oncology
  • E-7449
  • IDD-001
  • IDD-002
  • JNJ-64052781
  • lenalidomide
  • MAT-303
  • MT-3724
  • olaptesed pegol
  • ONO-4059
  • REGN-1979
  • SD-101
  • TAB-08
  • tocilizumab

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8339IDB

Summary

Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016', provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
  • The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects
  • The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • B-Cell Chronic Lymphocytic Leukemia Overview
  • Therapeutics Development
    • Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview
    • Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis
  • B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies
  • B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies
  • B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes
  • B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
    • AB Science SA
    • Aduro BioTech, Inc.
    • Amgen Inc.
    • Celgene Corporation
    • Cell Source, Inc.
    • Dynavax Technologies Corporation
    • Eisai Co., Ltd.
    • Elsalys Biotech SAS
    • F. Hoffmann-La Roche Ltd.
    • iDD biotech SAS
    • Immunomedics, Inc.
    • Johnson & Johnson
    • Juno Therapeutics Inc.
    • Lymphocyte Activation Technologies, S.A.
    • MedImmune, LLC
    • MEI Pharma, Inc.
    • Millennium Pharmaceuticals Inc
    • Molecular Templates Inc.
    • Noxxon Pharma AG
    • Ono Pharmaceutical Co., Ltd.
    • Regeneron Pharmaceuticals Inc
    • Sunesis Pharmaceuticals, Inc.
    • TheraMAB LLC
    • Unum Therapeutics, Inc.
  • B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 202-b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AB-8779 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alemtuzumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-319 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BION-1301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Hematological Malignancies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-7449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IDD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IDD-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-64052781 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAT-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ME-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mRNA ACTR + rituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-3724 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olaptesed pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-4059 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-1979 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNS-062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAB-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects
  • B-Cell Chronic Lymphocytic Leukemia - Discontinued Products
  • B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement
      • Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2016
  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech, Inc., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cell Source, Inc., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by MedImmune, LLC, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by MEI Pharma, Inc., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..2), H2 2016
  • B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2016
  • Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top